Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy
A panelist discusses how immunotherapy combined with chemotherapy has revolutionized recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment through improved survival outcomes demonstrated in landmark trials such as JUPITER-02 with toripalimab and KEYNOTE-590 with pembrolizumab, emphasizing that although most patients benefit regardless of PD-L1 status or Epstein-Barr virus positivity, clinicians must carefully consider patient-specific factors, such as performance status and comorbidities, alongside the management of unique immune-related adverse events through early recognition, established treatment algorithms, and multidisciplinary collaboration to optimize outcomes in this evolving treatment landscape.
Video content above is prompted by the following:
- Please further elaborate on your clinical experience and perception of immunotherapy in combination with chemotherapy for R/M NPC.
- What are your thoughts on the use of other immunotherapy agents, such as pembrolizumab?
- Overall, how do you see immunotherapy impacting the treatment landscape for R/M NPC?
- How would you determine which patients are best suited for immunotherapy?
- How do you foresee clinical practice adapting to incorporate immunotherapies?
- What factors are critical to consider when integrating immunotherapy into treatment protocols for R/M NPC?
- Please discuss other treatment considerations to consider with recurrent NPC.
- Please discuss potential adverse events and strategies to mitigate/manage risks.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
